What Is Echinacea and How Does It Work?
Echinacea is a genus of flowering plants in the daisy family, with Echinacea purpurea, Echinacea angustifolia, and Echinacea pallida being the most commonly used species in supplements. Different parts of the plant (roots, aerial parts, whole herb) contain different profiles of active compounds including alkamides, polysaccharides, glycoproteins, and caffeic acid derivatives.
Proposed mechanisms of action include stimulation of phagocytic activity in macrophages and neutrophils, induction of interferon production, and modulation of pro-inflammatory cytokines. The net biological effect is an apparent priming or upregulation of innate immune activity, which — in theory — could help the body respond more rapidly to respiratory pathogens.
A key complexity: because different preparations (species, plant part, extraction method, standardisation) vary enormously, comparing results across echinacea trials is methodologically challenging.
What the RCT and Meta-Analysis Evidence Shows
The most recent and comprehensive meta-analysis reviewed 24 double-blind RCTs and concluded that echinacea preparations reduced the incidence of common colds by approximately 10–35% and duration by 1–1.5 days, depending on the preparation tested and the population studied (Karsch-Völk et al., 2015). This was a Cochrane-associated review. The authors also noted substantial heterogeneity across trials.
A well-controlled RCT specifically using Echinacea purpurea found a statistically significant reduction in upper respiratory tract infection (URTI) episodes over a 4-month observation period in adults at elevated infection risk (Jawad et al., 2012). The preparation in this trial was well-characterised, making it one of the stronger individual study designs.
For treatment (shortening an existing cold), evidence is more modest. Several RCTs show a tendency toward shorter cold duration, but the effect is often small and not always statistically significant in individual studies.
Effect Sizes and Who Benefits
The strongest signals are in:
- Prevention: frequent travellers, office workers, those with high cold exposure during winter months
- People beginning to feel early cold symptoms — some data suggests starting echinacea at symptom onset may reduce duration
Effects appear more consistent in adult populations than in children, and in individuals with genuinely high immune challenge rather than a general wellness population.
EFSA-Approved Claims
EFSA has not approved any health claim for echinacea. However, the EMA (European Medicines Agency) Community Herbal Monograph recognises traditional use of Echinacea purpurea aerial parts for the symptomatic treatment of common colds and upper respiratory infections. This is a traditional use recognition, not a modern efficacy claim — but it does reflect regulatory acknowledgment of the herb's historical application.
Practical Considerations
For prevention, echinacea is typically used in cycles rather than continuously — for example, 8–10 weeks on, followed by a break — though evidence on optimal cycling is limited. For acute treatment, most studied protocols use it for 7–10 days at the onset of symptoms.
Ostrovit Echinacea 90caps is available at maxfit.ee in the ehhinaatsea category. It provides a convenient, standardised daily dose of echinacea extract suitable for seasonal immune support.
Echinacea is generally well tolerated. Rare allergic reactions have been reported, particularly in individuals with daisy-family (Asteraceae) plant allergies. It is not recommended during autoimmune conditions or for people on immunosuppressive medications without medical advice.
Honest Verdict
Echinacea sits in a relatively rare category among herbal supplements: one with genuine, replicated, peer-reviewed RCT evidence showing meaningful effects — even if modest. The reduction in cold incidence and duration observed in meta-analysis is real, though preparation-specific and not dramatic. EFSA has not approved specific efficacy claims, but EMA recognises traditional use. For seasonal cold prevention or early symptomatic use, echinacea is a reasonable, evidence-informed choice with a good safety profile.
FAQ
Does echinacea prevent colds?
Meta-analysis evidence suggests echinacea can reduce cold incidence by roughly 10–35% depending on the preparation (Karsch-Völk et al., 2015). This is a real but modest preventive effect. It should complement, not replace, foundational immune practices such as adequate sleep, vitamin D, and hand hygiene.
Should I take echinacea continuously or in cycles?
Most clinical trials have not studied long-term continuous use beyond a few months. Common practice is to use echinacea cyclically — typically 8 weeks of use followed by a break — based on theoretical concerns about immune habituation. Evidence for this cycling approach is limited, but it is widely recommended as a precautionary measure.
Which echinacea species is most effective?
Echinacea purpurea (aerial parts) has the most extensive human trial evidence, including the large Jawad et al. (2012) RCT. Product quality varies considerably; standardised extracts with documented alkamide or polysaccharide content are preferable to unstandardised products.
References
Karsch-Völk, M., Barrett, B., Kiefer, D., Bauer, R., Ardjomand-Woelkart, K., & Linde, K. (2015). Echinacea for preventing and treating the common cold. Cochrane Database of Systematic Reviews, 2015(2), CD000530.
Jawad, M., Schoop, R., Suter, A., Klein, P., & Eccles, R. (2012). Safety and efficacy profile of Echinacea purpurea to prevent common cold episodes: a randomized, double-blind, placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine, 2012, 841315. https://pubmed.ncbi.nlm.nih.gov/23024696/
Franke, R., & Schilcher, H. (2006). Relevance and use of chamomile (Matricaria recutita L.) in traditional herbal medicine. In M. Ramawat & J.-M. Mérillon (Eds.), Bioactive Molecules and Medicinal Plants. Springer.
